ALPMY News and Press, Astellas Pharma Inc. ADR From 05/21/21

AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...

Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy - Durable Responses Observed in Second Cohort of Patients in Pivotal E...

Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting Astellas' ambitious innovation and committed collaboration support new research on investigational and approved therapies in hard-to-treat cancers PR Newswire TOKYO , ...

Japan's Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application NDA, submitted in March, is for locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication PR Newswire TOKYO ,...

Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer Enzalutamide is now the only oral therapy approved by the European Commission to treat three distinct types of advanced prostate cancer PR Newswi...

Astellas Pharma, Inc. (ALPMF) Q4 2021 Earnings Conference Call April 27, 2021 1:00 AM ET Company Participants Kenji Yasukawa - President & CEO Naoki Okamura - Corporate EVP, Chief Strategy Officer and CFO Yukio Matsui - Chief Commercial Officer Bernie Zeiher - Chief Medical Officer Confer...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Astellas Pharma Inc. 2020 Q4 - Results - Earnings Call Presentation

Most companies in the pharmaceutical space received unprecedented attention amid the COVID-19 pandemic. And because the demand for their products and services is expected to increase in the coming months, we think it wise to bet now on undervalued pharma stocks Bristol-Myers (BMY), Sanofi (SN...

Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer - Priority Review Granted with Action Date of August 17 - - Australia and Canada...

Astellas' XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation - Confirmatory Phase 3 trial in China, other countries stopped early due to positive results at planned i...